Xgeva
Phase 3Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.Xgeva is one of 6 small molecule programs targeting Giant Cell Tumor. It is currently in Phase 3.
1
Indications
10
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Giant Cell Tumor
#DrugCompanyPhaseTrials
1IC-Green
PProvepharm SAS
Approved
Zometa
PfizerPhase 3
Romvimza
DDeciphera Pharmaceuticals, LLC
Phase 3
Narlumosbart
SShanghai JMT-Bio Inc.
Phase 3
Xgeva
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3
Pimicotinib（absk021）
AAbbisko Therapeutics Co, Ltd
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immunogenicity3 trials
Efficacy and Safety3 trials
Giant Cell Tumor1 trial
Adult1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Xgeva. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details